Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Annamaria, Petrungaro"'
Publikováno v:
Thalassemia Reports, Vol 12, Iss 2, Pp 30-33 (2022)
Transfusion-dependent thalassemia patients undergo transfusion immunomodulating effects, which result in a general immune response depression and, consequently, an increase in the frequency of infectious episodes and neoplastic events due to a reduct
Externí odkaz:
https://doaj.org/article/9e9fbcfe38a84edf9253b32da3cc1dfa
Publikováno v:
In Transfusion and Apheresis Science October 2020 59(5)
Publikováno v:
AIMS Medical Science. 9:362-366
Sickle cell disease (SCD) is a common inherited condition in African, Caribbean, and Mediterranean countries. SCD is a hematologic disorder caused by a well-characterized point mutation in the β-globin gene, which produces an abnormal hemoglobin S t
Publikováno v:
Transfusion and Apheresis Science. 58:647-651
Thalassemias and sickle cell disease are a group of inherited blood disorders caused by alterations of the synthesis or of the structure of hemoglobin chains. It results in variable outcomes ranging from severe anemia to clinically asymptomatic indiv
Autor:
Massimo Gentile, Valeria Magarotto, Massimo Offidani, Pellegrino Musto, Sara Bringhen, Maria Teresa Petrucci, Francesca Gay, Alessandra Larocca, Giuseppina Uccello, Annamaria Petrungaro, Ernesto Vigna, Rosa Greco, Anna Grazia Recchia, Giovanni Tripepi, Roberto Ria, Francesco Di Raimondo, Antonio Palumbo, Fortunato Morabito
Publikováno v:
American Journal of Hematology. 92:244-250
There are currently no direct head-to-head clinical trials evaluating bortezomib-melphalan-prednisone (VMP) versus lenalidomide and low-dose dexamethasone (Rd). VMP (257 cases) and Rd (222 cases) arms of two randomized phase III trials were employed
Autor:
Eugenio Lucia, Anna Grazia Recchia, Rosa Greco, Annamaria Petrungaro, Massimo Gentile, Ernesto Vigna, Francesco Mendicino, Carla Mazzone, Giuseppina Uccello, Fortunato Morabito
Publikováno v:
Expert Opinion on Pharmacotherapy. 18:133-137
Autor:
Annamaria Petrungaro, Sonia Cirrincione, Marco Ruggeri, Fabio Forghieri, Fabio Efficace, Iolanda Vincelli, Nicola Cascavilla, Giovanni Caocci, Franco Mandelli, Paolo Ditonno, Maria Gabriella Mazzucconi, Francesco Cottone, Monica Carpenedo, Alessandra Borchiellini, Laura Scaramucci, Cristina Santoro, Gianluca Gaidano, Paola Fazi, Francesco Rodeghiero, Valeria Di Giacomo, Micaela Bergamaschi, Maria Pina Simula, Alessandro Rambaldi
Publikováno v:
American Journal of Hematology. 91:995-1001
The main objective of this study was to compare health-related quality of life (HRQOL) of primary immune thrombocytopenia (pITP) patients with that of general population, overall, and by patient group (i.e., newly diagnosed, persistent, and chronic p
Autor:
Sabrina Bossio, Ernesto Vigna, Francesco Mendicino, Renzo Bonofiglio, Antonella La Russa, Fortunato Morabito, Dario Terzi, Massimo Gentile, Anna Grazia Recchia, Francesco Zinno, Anna Perri, Annamaria Petrungaro, Laura De Stefano
Publikováno v:
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 57(2)
Thrombotic thrombocytopenic purpura (TTP) is a rare microangiopathic hemolytic anemia (MAHA) defined by mechanical hemolytic anemia, severe thrombocytopenia, and systemic visceral ischemia due to systemic platelet-rich microthrombi. Forty percent of
Autor:
Angela Palummo, Nadia Caruso, Giuseppina Uccello, Massimo Gentile, Annamaria Petrungaro, Ernesto Vigna, Fortunato Morabito, Anna Grazia Recchia, Laura De Stefano, Sabrina Bossio, Francesca Storino, Massimo Martino
Publikováno v:
Expert opinion on investigational drugs. 26(11)
Venetoclax, an orally bioavailable inhibitor of BCL-2, was approved in 2016 by the United States Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia (CLL) patients with 17p deletion [del(17p)], who have received at le
Autor:
Sabrina Bossio, Anna Grazia Recchia, Angela Palummo, Giuseppina Uccello, Massimo Gentile, Rosellina Morelli, Ernesto Vigna, Carla Mazzone, Rosa Greco, Fortunato Morabito, Caterina Musolino, Annamaria Petrungaro, Laura De Stefano
We describe the case of a patient with Philadelphia-positive acute lymphoblastic leukemia treated with dasatinib plus steroids as first-line therapy, who achieved a major molecular response (MMR) before undergoing matched, unrelated donor allogeneic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e8bdbbd0ec55cefd1f4dfb0c6386820
http://hdl.handle.net/11570/3119842
http://hdl.handle.net/11570/3119842